Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663634 | 0.86 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1HSP90B1TRAP1CHRNA7 | |
| SCHEMBL184907 | 0.77 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL14123937 | 0.71 | HSP90AB1 (0.64) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1852028 | 0.68 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1304291 | 0.67 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1 | |
| SCHEMBL2268041 | 0.67 | HSP90AB1 (0.57) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1148585 | 0.66 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1 | |
| SCHEMBL12060302 | 0.66 | HSP90AB1 (0.66) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12047274 | 0.66 | HSP90AB1 (0.63) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3665914 | 0.65 | KEAP1 (0.38) | HSP90AA1HSP90AB1CHRNA7CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130345219-A1 | TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8524712-B2 | Triazinone and diazinone derivatives useful as HSP90 inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524712-B2 | Triazinone and diazinone derivatives useful as HSP90 inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2155694-B1 | TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100298331-A1 | TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2010-11-25 | — | — | US | disclosed |
| US-20100298331-A1 | TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2010-11-25 | — | — | US | disclosed |
| WO-2008118391-A2 | TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298331-A1 | TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20130345219-A1 | TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.